NR0B1 and hepatocellular carcinoma: PPARs, nuclear hormone receptors, could be activated by fatty acids and their derivatives and PPAR agonists are beneficial for the treatment of non-alcoholic fatty liver disease (NAFLD), liver fibrosis, and HCC (Cao et al., 2009).